AstraZeneca blames trial design for Phase 3 failure of bone disease drug
New details from AstraZeneca's failed Phase 3 trial of its enzyme replacement therapy for a genetic bone disease suggest the test missed its goals because of how the trial was composed, as the drugmaker seeks ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.